The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors;Perioperativer Umgang mit Antikoagulanzien und Thrombozytenaggregationshemmern

Deutsches Arzteblatt International

Volumn 110, Issue 31-32, 2013, Pages 525-532

  Schlitt, Axel ^a   Jámbor, Csilla ^b   Spannagl, Michael ^b   Gogarten, Wiebke ^c   Schilling, Tom ^d   Zwißler, Bernhard ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Munich Municipal Hospital   (Germany)

^d Klinikum Dorothea Christiane Erxleben Quedlinburg gGmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; RIVAROXABAN; TICAGRELOR;

ANTICOAGULATION; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG ELUTING STENT; DRUG USE; ELECTIVE SURGERY; HUMAN; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS; MONOTHERAPY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PUBLICATION; REVIEW; STENT THROMBOSIS; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; PREMEDICATION;

EID: 84883575677     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0525     Document Type: Review

References (40)

1. Graham I, Atar D, Borch-Johnsen K, Boysen G, et al.: European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375-414.
2. Lahtela H, Rubboli A, Schlitt A, et al.: AFCAS. Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. Circ J 2012; 76: 1363-8.
3. Camm AJ, Lip GYH, De Caterina R, et al.: 2012 focussed update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-47.
4. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC: Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630-9.
5. Pausieren von oralen Antikoagulanzien bei Vorhofflimmern ist risikoreich. Arzneimittelbrief 2013; 47: 4-5.
6. Trappe HJ: Atrial fibrillation: established an innovative methods of evaluation and treatment. Dtsch Arztebl Int 2012; 109: 1-7.
7. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, et al.: Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-96.
8. S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE). Version vom 18. März 2009 Registrierungsnummer: 003-001. www.awmf.org/uploads/tx-szleitlinien/003-001l-S3-Thromboembolie-Prophylaxe-2010.pdfAWMF.
9. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160-98.
10. Silber S, Albertsson P, Avilés FF, et al.: Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
11. Hess CN, Becker RC, Alexander JH, Lopes RD: Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician. J Thromb Thrombolysis 2012; 34: 552-61.
12. Raaz U, Maegdefessel L, Buerke M, Janusch M, Werdan K, Schlitt A: INR matters: a case on managing argatroban for bridging oral anticoagulation in a patient with heparin induced thrombocytopenia type II after mechanical heart valve replacement. Thromb Res 2009; 124: 242-3.
13. Schellong SM, Haas S: Neue orale Antikoagulanzien und ihre Anwendung im perioperativen Umfeld. Anasthesiol Intensivmed Notfallmed Schmerzther 2012; 47: 266-72.
14. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-79.
15. Zhou W, Schwarting S, Illanes S, et al.: Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-99.
16. Kaatz S, Kouides PA, Garcia DA, et al.: Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 Suppl 1: 141-5.
17. Mega JL, Close SL, Wiviott SD, et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.: High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-10.
19. Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
20. Bhatt DL: Prasugrel in clinical practice. N Engl J Med 2009; 361: 940-2.
21. Wallentin L: P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30: 1964-77.
22. Roe MT, Armstrong PW, Fox KA, et al.: TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-309.
23. Wallentin L, Becker RC, Budaj A, et al.: Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045-57.
24. Teng R, Butler K: Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487-96.
25. Giannitsis E, Katus HA: Antiplatelet therapy-ticagrelor. Hamostaseologie 2012; 32: 177-85.
26. Burger W, Chemnitius JM, Kneissl GD, Rucker G: Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 2005; 257: 399-414.
27. Poldermans D, Bax JJ, Boersma E, et al.: Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009; 30: 2769-812.
28. Wolff T, Miller T, Ko S: Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405-10.
29. Korte W, Cattaneo M, Chassot PG, et al.: Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743-9.
30. nd revised recommendation der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin. Anästh Intensivmedizin 2007; 48: 109-24.
31. Grines CL, Bonow RO, Casey DE, et al.: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734-9.
32. Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H: Coronary artery stenting and non-cardiac surgery-a prospective outcome study. Br J Anaesth 2006; 96: 686-93.
33. Bonzel T, Erbel R, Hamm CW, et al.: Perkutane Koronarinterventionen (PCI). Clin Res Cardiol 2008; 97: 513-47.
34. Iakovou I, Schmidt T, Bonizzoni E, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30.
35. Newsome LT, Kutcher MA, Royster RL: Coronary artery stents: Part I. Evolution of percutaneous coronary intervention. Anesth Analg 2008; 107: 552-69.
36. Schouten O, van Domburg RT, Bax JJ, et al.: Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49: 122-4.
37. Stettler C, Wandel S, Allemann S, et al.: Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis. Lancet 2007; 370: 937-48.
38. Rhee SJ, Yun KH, Lee SR, Chae JK, Nam CW, Jun DH, Jeong JW: Drug-eluting stent thrombosis during perioperative period. Int Heart J 2008; 49: 135-42.
39. Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, Melby S, Berger PB: Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003; 42: 234-40.
40. Hamm CW, Bassand JP, Agewall S, et al.: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.